Breakfast (7:30-9:00)

Morning Session

Session A: Chair Martin Schrappe, Germany
1. BCR::ABL1, Ph-Like ALL and T-ALL with ABL-class mutations (9:00-10:00)
• Next Frontline Trial (Andrea Biondi, Italy, Mignon Loh, US, Lewis Silverman, US)
• Relapse Outcomes (Maria Grazia Valsecchi, Italy, Mignon Loh, US)
• ABL-class in T-ALL (Sarah Elitzur, Israel)
• ABL-class resistance mutations in B-ALL (Rob Pieters, Netherlands, Monique den Boer, Netherlands)
• Imatinib PK (Inge van der Sluis, Netherlands, Kjeld Scmiegelow, Denmark)

2. TCF3::PBX1 and TCF3::HLF ALL (10:00-10:45)
• TCF3::PBX1 (Andre Baruchel, France and Stephen Hunger, US)
• TCF3::HLF (Andre Baruchel, France and Stephen Hunger, US)
• Outcomes and Treatment of relapse, impact of immunotherapy on outcomes, biologic and preclinical data (Jean Pierre Bourquin, Switzerland)

Coffee/Tea Break (10:45-11:15)

Session B: Chair Robert Pieters, Netherlands
3. Induction Death (Lewis Silverman, US) (11:15-11:30)
4. Infant ALL (11:30-12:15)
• Infant ALL Omic Initiatives (new project: MLL-germline and NUTM1-germline) (Giovanni Cazzaniga, Italy, Anke Bergmann, Germany and Daisuke Tomizawa, Japan)

Lunch (12:15-1:45)

Afternoon Session

Session C: Chair Mats Heyman, Sweden
5. T-ALL (1:45-3:00)
• Defining High-Risk T-ALL (Mats Heyman, Sweden, Gunnar Cario, Germany, Sophie Degerman, Sweden, Dave Teachey US)
• Rare High-Risk and Low-Risk Genomic Groups (SPI1, LMO2 yd, HOXA9-TCR, RPL10, NOTCH1 intragenic loss) (New Project) (Dave Teachey, US, Charles Mullighan, US, Anthony Moorman, UK, Hiroto Inaba, US)
• Use of TKIs in T-ALL (Jean-Pierre Bourquin, Switzerland)

Coffee/Tea Break (3:00-3:30)

Session D: Chair Ching-Hon Pui, USA
6. T21 Omics (3:30-4:30)
• IKZF1 (Oskar Haas, Austria)
• CEPBalt, IGF2BP1, PAX5alt, and CRLF2 (New Project) (Oskar Haas, Austria, Mignon Loh, US, Mary Shago, US)

Dinner